Journal ArticleDOI
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Laurent Ducry,Bernhard Stump +1 more
Reads0
Chats0
TLDR
Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of cytotoxic molecules, thereby taking advantage of the best characteristics of both components.About:
This article is published in Bioconjugate Chemistry.The article was published on 2010-01-01. It has received 612 citations till now. The article focuses on the topics: Monoclonal antibody.read more
Citations
More filters
Journal ArticleDOI
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
TL;DR: This review offers a detailed description of different cytotoxic drug carriers, such as liposomes, carbon nanotubes, dendrimers, polymeric micelles,polymeric conjugates and polymeric nanoparticles, in passive and active targeted cancer therapy, by enhancing the permeability and retention or by the functionalization of the surface of the carriers.
Journal ArticleDOI
Antibody–drug conjugates: targeted drug delivery for cancer
TL;DR: The antibody-drug conjugate field has made significant progress recently owing to careful optimization of several parameters, including mAb specificity, drug potency, linker technology, and the stoichiometry and placement of conjugated drugs.
Journal ArticleDOI
Site-specific antibody drug conjugates for cancer therapy
TL;DR: Various site-specific conjugation strategies that are currently used for the production of ADCs are reviewed, including use of engineered cysteine residues, unnatural amino acids, and enzymatic conjugations through glycotransferases and transglutaminases.
Journal ArticleDOI
In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug.
Xumeng Wu,Xuanrong Sun,Zhiqian Guo,Jianbin Tang,Youqing Shen,Tony D. James,He Tian,Weihong Zhu +7 more
TL;DR: The tumor-targeting ability and the specific drug release in tumors make DCM-S-CPT as a promising prodrug, providing significant advances toward deeper understanding and exploration of theranostic drug-delivery systems.
References
More filters
Journal ArticleDOI
Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Svetlana O. Doronina,Brian E. Toki,Michael Torgov,Brian A. Mendelsohn,Charles G. Cerveny,Dana F. Chace,Ron L. DeBlanc,R Patrick Gearing,Tim D. Bovee,Clay B. Siegall,Joseph A. Francisco,Alan F. Wahl,Damon L. Meyer,Peter D. Senter +13 more
TL;DR: The in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylaurists E (MMAE), linked to the chimeric mAbs cBR96 and cAC10, illustrate the importance of linker technology, drug potency and conjugation methodology in developing safe and efficacious mAb-drug conjugs for cancer therapy.
Journal ArticleDOI
Arming antibodies: prospects and challenges for immunoconjugates
Anna M. Wu,Peter D. Senter +1 more
TL;DR: For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.
Journal ArticleDOI
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
Kevin J. Hamblett,Peter D. Senter,Dana F. Chace,Michael M. C. Sun,Joel S. Lenox,Charles G. Cerveny,Kim M. Kissler,Starr X. Bernhardt,Anastasia K. Kopcha,Roger F. Zabinski,Damon L. Meyer,Joseph A. Francisco +11 more
TL;DR: By decreasing drug loading per antibody, the therapeutic index was increased demonstrating that drug loading is a key design parameter for antibody-drug conjugates.
Journal ArticleDOI
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
Joseph A. Francisco,Charles G. Cerveny,Damon L. Meyer,Bruce J. Mixan,Kerry Klussman,Dana F. Chace,Starr X. Rejniak,Kristine A. Gordon,Ronald DeBlanc,Brian E. Toki,Che-Leung Law,Svetlana O. Doronina,Clay B. Siegall,Peter D. Senter,Alan F. Wahl +14 more
TL;DR: CAC10-vcMMAE was highly potent and selective against CD30+ tumor lines but was more than 300-fold less active on antigen-negative cells in SCID mouse xenograft models of anaplastic large cell lymphoma or Hodgkin disease, and was efficacious at doses as low as 1 mg/kg.
Journal ArticleDOI
Targeted cancer therapy: conferring specificity to cytotoxic drugs.
TL;DR: The antitumor activity of these targeted agents was superior to that of the antibodies alone or the standard anticancer drugs in human tumor xenograft models and opens the door to the future development of highly potent drugs that were too toxic on their own to be therapeutically useful.
Related Papers (5)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath Reddy Junutula,Helga Raab,Suzanna Clark,Sunil Bhakta,Douglas D. Leipold,Sylvia Weir,Yvonne Chen,Michelle Simpson,Siao Ping Tsai,Mark S. Dennis,Yanmei Lu,Y Gloria Meng,Carl Ng,Jihong Yang,Chien C Lee,Eileen T. Duenas,Jeffrey Gorrell,Viswanatham Katta,Amy Kim,Kevin McDorman,Kevin McDorman,Kelly Flagella,Rayna Venook,Sarajane Ross,Susan D. Spencer,Wai Lee Wong,Henry B. Lowman,Richard Vandlen,Mark X. Sliwkowski,Richard H. Scheller,Paul Polakis,William Mallet +31 more
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen,Keyang Xu,Luna Liu,Helga Raab,Sunil Bhakta,Margaret Kenrick,Kathryn L Parsons-Reponte,Janet Tien,Shang-Fan Yu,Elaine Mai,Dongwei Li,Jay Tibbitts,Jakub Baudys,Ola Saad,Suzie J. Scales,Paul J. Mcdonald,Philip E. Hass,Charles Eigenbrot,Trung Nguyen,Willy Solis,Reina N. Fuji,Kelly Flagella,Darshana Ramesh Patel,Susan D. Spencer,Leslie A. Khawli,Allen J. Ebens,Wai Lee Wong,Richard Vandlen,Surinder Kaur,Mark X. Sliwkowski,Richard H. Scheller,Paul Polakis,Jagath Reddy Junutula +32 more